Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 8/20 | 0.46 |
| ▸ | RAB9A | P51151 | 6/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | MPL | P40238 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1313889 | 0.80 | CYP1A2 (0.52) | TP53MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20507148 | 0.76 | CA12 (0.46) | TP53NPC1RAB9AL3MBTL1SMN1; SMN2 | |
| SCHEMBL4277391 | 0.75 | TP53 (0.59) | TP53MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1312698 | 0.75 | RAB9A (0.55) | MAPTNPC1RAB9AL3MBTL1SMN1; SMN2 | |
| SCHEMBL20263263 | 0.74 | MAPT (0.57) | TP53MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17011150 | 0.74 | TP53 (0.57) | TP53MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6774267 | 0.74 | CNR2 (0.44) | TP53MAPTNPC1RAB9AL3MBTL1 | |
| SCHEMBL16199151 | 0.74 | NPC1 (0.47) | TP53MAPTNPC1RAB9AL3MBTL1 | |
| SCHEMBL20507136 | 0.72 | PTGS2 (0.48) | MAPTNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL12299893 | 0.72 | SMN1; SMN2 (0.47) | TP53MAPTNPC1RAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | IPS HEART | 2018-09-27 | — | — | US | claimed |
| US-20210054344-A1 | CPC EXOSOMES MIRNA373 COMBINATION THERAPIES | IPS HEART | 2021-02-25 | — | — | US | disclosed |
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | IPS HEART | 2018-09-27 | — | — | US | disclosed |
| CN-104470521-B | Neprilysin inhibitors | 施万生物制药研发IP有限责任公司 | 2017-04-12 | — | — | CN | disclosed |
| US-20090286806-A1 | ISOXAZOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-11-19 | — | — | US | disclosed |
| US-20090286806-A1 | ISOXAZOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-11-19 | — | — | US | disclosed |
| US-20090286806-A1 | ISOXAZOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-11-19 | — | — | US | disclosed |
| EP-2007759-A1 | ISOXAZOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007118323-A1 | ISOXAZOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007118323-A1 | ISOXAZOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | EXOSC9, EXOSC5, EXOSC4 | TP53 3565/4885MAPT 2473/4885NPC1 1167/4885 |
| US-20090286806-A1 | ISOXAZOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1G, CACNA1S | TP53 4858/4885MAPT 3579/4885NPC1 1198/4885 |
| US-20210054344-A1 | CPC EXOSOMES MIRNA373 COMBINATION THERAPIES | EXOSC5, UTRN, EXOSC4 | TP53 1273/4885MAPT 3306/4885NPC1 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.